Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCSDaiichi Sankyo2023-11-10 06:54:38Daiichi Sankyo to Present New Data for HER2 and HER3 Directed DXd ADCs at SABCS
-
DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive Early Breast Cancer at High Risk After Neo-adjuvant TherapyDaiichi Sankyo2023-11-09 21:02:38DESTINY-Breast05 Head-to-Head Phase 3 Trial of ENHERTU® Versus T-DM1 Initiated in Patients with HER2 Positive
-
ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-09 21:02:11ENHERTU® Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer
-
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T CellsDaiichi Sankyo2023-11-09 21:01:48Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated
-
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric CancerDaiichi Sankyo2023-11-09 21:01:36ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Cancer
-
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with EGFR-Mutated NSCLC at ESMO 2020Daiichi Sankyo2023-11-09 21:01:17Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Patients with
-
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal CancerDaiichi Sankyo2020-09-15 15:08:35Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced
-
Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be Presented at 2020 ESMO Annual MeetingDaiichi Sankyo2023-11-09 20:59:40Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSCLC to be
-
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast CancerDaiichi Sankyo2023-11-09 20:58:33EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive
-
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 TrialDaiichi Sankyo2023-11-09 20:56:34ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in
